Our results emphasize the need for the inclusion of TP53 in the genetic testing algorithm, in addition to BRCA1 and BRCA2 analysis, in all women diagnosed with breast cancer at young onset [34]. This evidence concerns the gene BRCA1 and breast carcinoma.